Technical Analysis for INFI - Infinity Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 1.76 2.33% 0.04
INFI closed up 2.33 percent on Friday, March 22, 2019, on 1.2 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical INFI trend table...

Date Alert Name Type % Chg
Mar 22 200 DMA Resistance Bearish 0.00%
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Calm After Storm Range Contraction 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 21 200 DMA Resistance Bearish 2.33%
Mar 21 Calm After Storm Range Contraction 2.33%
Mar 21 Outside Day Range Expansion 2.33%
Mar 20 Fell Below 200 DMA Bearish 1.15%
Mar 20 Calm After Storm Range Contraction 1.15%

Older signals for INFI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase IIa study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase II signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Diseases Chemical Substances Drug Discovery Inflammation Non Small Cell Lung Cancer Rheumatoid Arthritis Hematologic Malignancies Phosphoinositide 3 Kinase Inhibitor Pyrimidines Allergic Asthma Nsclc
Is INFI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.92
52 Week Low 1.0
Average Volume 236,601
200-Day Moving Average 1.786
50-Day Moving Average 1.4487
20-Day Moving Average 1.6535
10-Day Moving Average 1.703
Average True Range 0.1448
ADX 39.51
+DI 24.9951
-DI 10.844
Chandelier Exit (Long, 3 ATRs ) 1.5156
Chandelier Exit (Short, 3 ATRs ) 1.7344
Upper Bollinger Band 1.8919
Lower Bollinger Band 1.4151
Percent B (%b) 0.72
BandWidth 28.835803
MACD Line 0.09
MACD Signal Line 0.0866
MACD Histogram 0.0035
Fundamentals Value
Market Cap 89.21 Million
Num Shares 50.7 Million
EPS -1.39
Price-to-Earnings (P/E) Ratio -1.27
Price-to-Sales 0.00
Price-to-Book 1.82
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.91
Resistance 3 (R3) 1.91 1.85 1.89
Resistance 2 (R2) 1.85 1.82 1.86 1.88
Resistance 1 (R1) 1.81 1.79 1.83 1.81 1.87
Pivot Point 1.75 1.75 1.77 1.76 1.75
Support 1 (S1) 1.71 1.72 1.73 1.71 1.65
Support 2 (S2) 1.65 1.69 1.66 1.64
Support 3 (S3) 1.61 1.65 1.64
Support 4 (S4) 1.61